AC Immune (ACIU) Capital Expenditures (2015 - 2025)

AC Immune (ACIU) has 11 years of Capital Expenditures data on file, last reported at -$133875.2 in Q4 2025.

• On a quarterly basis, Capital Expenditures fell 30.31% year-over-year to -$133875.2 in Q4 2025; TTM through Dec 2025 was -$1.1 million, a 60.96% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 million, down 65.09% from the prior year.
• Capital Expenditures for Q4 2025 stood at -$133875.2, down from -$72506.4 in the prior quarter.
• Over the last five years, Capital Expenditures for ACIU reached as high as $4.9 million in Q4 2021 and fell as low as -$873786.7 in Q1 2021.
• Historically, Capital Expenditures has averaged $74110.8 across 5 years, with a median of -$205646.8 in 2023.
• Across the five-year window, Capital Expenditures jumped 76.76% in 2022 and plunged 499.17% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $4.9 million in 2021, then slumped by 48.71% to $2.5 million in 2022, then tumbled by 107.4% to -$187140.8 in 2023, then soared by 45.1% to -$102737.0 in 2024, then plunged by 30.31% to -$133875.2 in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$133875.2 in Q4 2025, -$72506.4 in Q3 2025, and -$450543.1 in Q2 2025.